2 weeks Ago By ABMN Staff
Erasca, Inc. ( NASDAQ:ERAS – Get Free Report ) was the recipient of a large increase in short interest in September. As of September 15th, there was short interest totalling 27,030,000 shares, an increase of 8.
9% from the August 31st total of 24,810,000 shares. Based on an average daily volume of 2,450,000 shares, the short-interest ratio is presently 11.0 days.
Currently, 15.4% of the shares of the stock are sold short. Institutional Investors Weigh In On Erasca Several institutional investors have recently bought and sold shares of the company.
Vanguard Group Inc. boosted its holdings in shares of Erasca by 14.4% during the 1st quarter.
Vanguard Group Inc. now owns 4,338,108 shares of the company’s stock worth $8,937,000 after purchasing an additional 545,765 shares during the last quarter. Acadian Asset Management LLC boosted its holdings in shares of Erasca by 286.
5% during the 1st quarter. Acadian Asset Management LLC now owns 346,953 shares of the company’s stock worth $713,000 after purchasing an additional 257,174 shares during the last quarter. CVI Holdings LLC acquired a new position in shares of Erasca during the 1st quarter worth approximately $3,000,000.
Sierra Summit Advisors LLC acquired a new position in shares of Erasca during the 4th quarter worth approximately $225,000. Finally, Logos Global Management LP acquired a new position in shares of Erasca during the 2nd quarter worth approximately $13,924,000. 67.
78% of the stock is currently owned by institutional investors and hedge funds. Wall Street Analysts Forecast Growth Several brokerages recently weighed in on ERAS. The Goldman Sachs Group cut their price target on Erasca from $4.
00 to $3.00 and set a “buy” rating for the company in a research note on Wednesday, August 14th. HC Wainwright lifted their price target on Erasca from $5.
00 to $6.00 and gave the company a “buy” rating in a research note on Tuesday, August 13th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock.
According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $6.00.
Erasca Price Performance ERAS stock traded down $0.14 during trading on Tuesday, hitting $2.59.
The stock had a trading volume of 1,561,730 shares, compared to its average volume of 1,653,184. Erasca has a twelve month low of $1.51 and a twelve month high of $3.
45. The stock has a market capitalization of $449.00 million, a P/E ratio of -3.
08 and a beta of 1.16. The company’s 50-day moving average price is $2.
84 and its two-hundred day moving average price is $2.46. Erasca ( NASDAQ:ERAS – Get Free Report ) last posted its quarterly earnings data on Monday, August 12th.
The company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.
12). As a group, sell-side analysts expect that Erasca will post -0.91 EPS for the current fiscal year.
Erasca Company Profile ( Get Free Report ) Erasca, Inc, a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. Read More Receive News & Ratings for Erasca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Erasca and related companies with MarketBeat.
com's FREE daily email newsletter ..
